论文部分内容阅读
目的 :了解第二代吲哚美辛 VCu IUD的临床疗效。方法 :自 1 997.5～ 1 998.2 ,在包括城市和农村的 6个临床单位 ,放置第二代吲哚美辛 VCu IUD1 0 0 0 (V组 )例 ;放置后 6月、1 2月和 2 4月随访 ,并与 1 0 0 0例放置 TCu3 80 A IUD者 (T组 )比较。结果 :两组对象临床特征相仿。随访率 98.2 5 %。净累积续用率随访 6月时 T组 95 .5 % ,V组 97.5 % (P<0 .0 5 ) ;1 2月时分别为 93 .79%和94.78% ;2 4月时分别为 88.2 3 %和 89.77%。脱落率在各阶段均为 T组高于 V组。妊娠率和因出血、疼痛取出率两组基本相似。月经量多、经期延长和腹痛的发生率 T组始终高于 V组。点滴出血者在 1 2月内 T组多于 V组。 V组月经量减少者始终多于 T组。在置器 4～ 6月 ,T组总 B/S、平均B/S及最大 B/S段长均大于 V组 (P<0 .0 1 )。血红蛋白测定在放 IUD前两组相似 ,随访 2 4月时复查 ,T组较放置前有所下降 (P<0 .0 0 1 ) ,且低于 V组 (P<0 .0 0 1 ) ;V组与放置前相似。结论 :第二代吲哚美辛 VCu与 TCu3 80 A比较 ,具有相同的避孕效果及续用率 ,较低的出血、疼痛副反应 ,更有利于保护妇女的生殖健康 ,值得临床推广应用
Objective: To understand the clinical efficacy of the second-generation indomethacin VCu IUD. Methods: From 1 997.5 to 1 988.2, the second generation indomethacin VCu IUD1 0 0 (group V) was placed in 6 clinical units including urban and rural areas. After 6 months, 1 month and 12 months Month follow-up, and compared with 100 cases of TCu3 80 A IUD (T group). Results: The clinical features of the two groups were similar. Follow-up rate of 98.2 5%. The net cumulative renewal rate was 95.5% in the T group at 6 months, 97.5% in the V group (P <0.05), 93.79% and 94.78% respectively at 1 month and 88.2 3% and 89.77%. The rate of shedding was higher in group T than in group V in all stages. Pregnancy rates and bleeding due to the removal of pain were similar in two groups. Menstrual flow, prolonged menstrual cramps and the incidence of abdominal pain group T is always higher than the V group. Dripping bleeding in 12 months in the T group more than V group. V group menstrual volume decreased always more than T group. From April to June, the total B / S, average B / S and maximum B / S length in T group were longer than those in V group (P <0.01). The hemoglobin was similar in the two groups before IUD release. The follow - up was performed at 24 months of follow - up. The level of hemoglobin in group T decreased slightly (P <0.01) and was lower than that in group V (P <0.01). Group V is similar to before placement. Conclusions: Compared with TCu3 80 A, the second-generation indomethacin VCu has the same contraceptive effect and continuous use rate, low bleeding and painful side effects, which is more conducive to the protection of women’s reproductive health and deserves clinical application